NCT01010373View on ClinicalTrials.gov

Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients

PHASE2SuspendedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

AS101

3 mg/m2 AS101 will be given intravenously (IV) three times per week.

Trial Locations (1)

Unknown

Sheba Medical Center, Tel Litwinsky

Sponsors

Lead Sponsor

BioMAS Ltd
All Listed Sponsors
lead

BioMAS Ltd

INDUSTRY